Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 192

Results For "disease"

2317 News Found

Prof. Jason Kovacic bags Agilent Thought Leader award
News | January 11, 2022

Prof. Jason Kovacic bags Agilent Thought Leader award

Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer
Biotech | January 11, 2022

Merck’s KEYTRUDA shows promise as adjuvant treatment for non-small cell lung cancer

First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC


Pfizer and Beam enter research collaboration for In Vivo base editing programme
Biotech | January 11, 2022

Pfizer and Beam enter research collaboration for In Vivo base editing programme

Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies


Immune Biosolutions lead immunotherapy product neutralises Covid-19
Biotech | January 11, 2022

Immune Biosolutions lead immunotherapy product neutralises Covid-19

In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract


Molnupiravir best option to treat Covid-19 now: Experts
News | January 11, 2022

Molnupiravir best option to treat Covid-19 now: Experts

Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Novartis and Molecular Partners report positive data for anti-viral Covid therapy
Biotech | January 10, 2022

Novartis and Molecular Partners report positive data for anti-viral Covid therapy

Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days


Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report
News | January 10, 2022

Clarivate identifies seven potential blockbuster drugs in Annual Drugs to Watch report

Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma


Bayer and Mammoth Biosciences to collaborate on gene editing technology
Biotech | January 10, 2022

Bayer and Mammoth Biosciences to collaborate on gene editing technology

Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones